RCS - EKF Diagnostics Hldg - Upgraded Product launch and Contract Wins

EKF Diagnostics HoldingsAnnouncement

18/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240718:nRSR8285Wa&default-theme=true

RNS Number : 8285W  EKF Diagnostics Holdings PLC  18 July 2024

EKF Diagnostics Holdings plc

("EKF", the "Company", or the "Group")

 

Upgraded Product launch and Contract Wins

 

Global launch of new Biosen analyzer

Two contracts in Asia with The Red Cross

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces the launch of its new and enhanced Biosen C-Line, an
industry leading benchtop glucose and lactate analyzer within its Point of
Care ("POC") range, in response to customer demands for greater connectivity
options and improved usability. EKF also announces it has secured new contract
wins from two tenders: Hong Kong Red Cross (three years) and Thai Red Cross
(two years) worth approximately £600k in total.

 

The Biosen C-Line (the "Biosen") is an easy-to-use, POC analyzer which
accurately measures glucose and lactate levels in healthcare and sports
performance. The Biosen is used by clinical professionals in both primary and
secondary care settings around the world to provide fast and accurate glucose
analysis for the detection and management of diabetes, a chronic condition
which is expected to affect 1.31 billion people worldwide by 2050 1 . The
Biosen is also the first choice for elite sports professionals, including
international football and Olympic teams, to measure lactate production during
training, which provides valuable insights into athletes' metabolic responses
during training and competition to help achieve peak performance.

 

The updated Biosen range uses the same proven technology as its predecessor to
provide precise and rapid measurements of glucose and lactate levels in whole
blood, plasma and serum with just one test. The new version has been enhanced
with improved connectivity, and is fully compatible with EKF Link
(https://www.ekfdiagnostics.com/ekf-link.html) , a middleware solution for
healthcare providers to manage their POC analyzers on one centralised platform
to enable the real-time remote management of data. EKF Link is a fast and
secure method for connecting POC devices to hospital and laboratory IT
systems, enabling the safe transfer of data from the analyzer to the hospital
or laboratory database for subsequent processing.

 

Integration of technology systems and advanced connectivity is becoming
increasingly important to healthcare providers and laboratories around the
world, as they look to improve resource utilisation and efficiencies. The
addition of EKF Link to the Company's POC portfolio has opened up a number of
new tender opportunities around the world, including the Hong Kong and Thai
Red Cross partnerships and will continue to aid the Company's growth in the
blood bank market globally.

 

New Biosen C-Line

 

 

A user-friendly, enhanced version of the EKF Biosen C-Line (above) has a new
look and feel with a colour touchscreen and multi-language capabilities, as
well as added connectivity with EKF Link

 

Julian Baines, Executive Chair of EKF Diagnostics plc, said: "The launch of
the new and enhanced Biosen is in line with our strategy to focus our R&D
on developing existing, high-growth, high-margin products and we continue to
lead and innovate in this space. We are also encouraged by the growing demand
for EKF Link, which is compatible with the EKF POC portfolio as well as other
devices, and has improved our competitive positioning, opening a number of new
tender opportunities around the world."

 

Learn more about the EKF Biosen C-Line analyzer measuring glucose and lactate
levels in whole blood, plasma and serum (https://www.ekfdiagnostics.com/biosen
(https://www.ekfdiagnostics.com/biosen) ) and also explore other EKF products:

https://www.ekfdiagnostics.com/
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ekfdiagnostics.com_&d=DwMFAw&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=HGalgl7KP7vrlweMAN9MrYrqge-8vcBk6BZF5tgRFjw&m=XQdHIkqwixlM1ucj0QeZl-BEIZvR7K6fzwkx_5-enOfeOdAE3yON9eXaNjZ1D-a5&s=UByncj7AtOEgnw1DnhwkWZnN1XOThWghLUfqkDrSNi8&e=)
.

 

 

For more information visit:

 

 EKF Diagnostics Holdings plc    www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair   via Walbrook PR
 Stephen Young, CFO

 Singer Capital Markets (Nominated Adviser & Broker)                      Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited             Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Charlotte Edgar

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com/) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes

 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

Details of the Contract Wins

EKF won two tenders in a competitive process: a three-year contract with the
Hong Kong Red Cross and a two-year contract with the Thai Red Cross.

 

The new contract with the Hong Kong Red Cross is to provide the following:

·    65 Hemo Control Hemoglobin Analyzers

·    870K tests

·    Installation of EKF Link to integrate and connect devices to HKRC
data management

 

The Thai Red Cross contract is to provide:

·    233 DiaSpect (TM) hand-held haemoglobin analysers

·    2.5M DiaSpect tests cuvette

 1  The Lancet and The Lancet Diabetes & Endocrinology journals
(https://www.thelancet.com/series/global-inequity-diabetes) (June 2023)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUBANRSOUBAAR